Ebola Vaccination Campaign Begins in the Democratic Republic of Congo
Table of Contents
A vaccination campaign targeting frontline workers and individuals infected with Ebola has commenced in the Democratic Republic of Congo (DRC). This initiative, announced by the World Health Association (WHO) on September 14, 2025, aims to control a recent outbreak of the deadly virus.
Understanding the Current Outbreak
The outbreak is centered in Bulape, located in the Kasai province of the DRC, which shares a border with Angola. Ebola virus disease (EVD), commonly known as ebola, is a severe, often fatal illness in humans. It’s transmitted to people from wild animals and spreads among humans through direct contact with bodily fluids of infected people, or with contaminated objects (like needles).
What is Ebola?
Ebola is caused by several different species of the Ebolavirus. Symptoms typically include fever, fatigue, muscle pain, headache, and sore throat, which can progress to vomiting, diarrhea, rash, and internal and external bleeding. The virus has a high fatality rate, varying depending on the strain and the quality of healthcare available.
The Vaccination Campaign: Ervebo
The initial deployment consists of 400 doses of the Ervebo Ebola vaccine, drawn from the DRC’s existing stockpile of 2,000 doses. Ervebo is a single-dose vaccine developed by Merck & Co. and approved by the U.S. Food and Drug Administration (FDA) and the WHO for the prevention of Ebola virus disease caused by the Zaire ebolavirus species.It has demonstrated important efficacy in previous outbreaks.
How Ervebo Works
Ervebo is a recombinant vesicular stomatitis virus (rVSV) vaccine. It contains a gene from the Zaire ebolavirus, but it is indeed not infectious and cannot cause Ebola. The vaccine works by triggering an immune response in the body, preparing it to fight off the virus if exposed. The single-dose nature of Ervebo simplifies logistics and allows for rapid deployment during outbreaks.
WHO’s Response and Ongoing Efforts
The WHO is actively supporting the DRC government in its response to the outbreak. This includes providing technical guidance, deploying personnel, and coordinating the vaccination campaign. Beyond vaccination, control measures include:
- Contact Tracing: Identifying and monitoring individuals who have come into contact with infected people.
- Isolation and Treatment: providing care for infected individuals in dedicated treatment centers.
- Safe Burial Practices: ensuring that the deceased are buried safely to prevent further transmission.
- Community engagement: Educating communities about the virus and promoting preventative measures.
Key Takeaways
- An Ebola vaccination campaign has begun in the DRC following a recent outbreak.
- The Ervebo vaccine, proven effective in past outbreaks, is being used.
- The WHO is providing support to the DRC government in controlling the outbreak.
- Control measures extend beyond vaccination to include contact tracing, isolation, safe burials, and community engagement.
The situation remains fluid, and the WHO will continue to monitor the outbreak closely and provide updates as they become available. Effective outbreak response relies on swift action, international collaboration, and community participation.
Source: WHO Regional Office for Africa